Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:administered_by |
healthcare professional
|
| gptkbp:administration_duration |
30 minutes
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:class |
antineoplastic agent
|
| gptkbp:clinical_trial |
gptkb:Oncology
gptkb:triple-negative_breast_cancer global Phase III demonstrated efficacy improved survival rates urothelial carcinoma long-term follow-up studies ongoing reduced tumor size |
| gptkbp:clinical_use |
oncology
|
| gptkbp:contraindication |
hypersensitivity to atezolizumab
|
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:drug_interactions |
none significant
|
| gptkbp:excretion |
primarily through urine
|
| gptkbp:financial_support |
available
|
| gptkbp:history |
developed by Genentech
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tecentriq
|
| gptkbp:ingredients |
gptkb:atezolizumab
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
liver function tests
complete blood count renal function tests |
| gptkbp:manufacturer |
gptkb:Genentech
|
| gptkbp:market_position |
global markets
|
| gptkbp:marketed_as |
gptkb:2016
|
| gptkbp:mechanism_of_action |
immune checkpoint inhibitor
|
| gptkbp:metabolism |
not extensively metabolized
|
| gptkbp:patient_education |
adherence to treatment schedule
report any signs of infection importance of follow-up appointments report any unusual bleeding or bruising |
| gptkbp:patient_population |
adults
|
| gptkbp:price |
varies by region
|
| gptkbp:provides_guidance_on |
included in ASCO guidelines
included in NCCN guidelines |
| gptkbp:publication |
numerous peer-reviewed articles
|
| gptkbp:regulatory_compliance |
approved for multiple indications
|
| gptkbp:research_focus |
cancer immunotherapy
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:safety_measures |
ongoing
|
| gptkbp:service_frequency |
every 2 to 3 weeks
|
| gptkbp:side_effect |
fatigue
nausea hepatitis diarrhea skin reactions pneumonitis colitis endocrinopathies immune-mediated reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:structure |
gptkb:Ig_G1
|
| gptkbp:targets |
gptkb:PD-L1
|
| gptkbp:treatment |
with chemotherapy
with targeted therapies |
| gptkbp:type_of_insurance |
may vary by plan
|
| gptkbp:used_for |
treatment of cancer
|
| gptkbp:bfsParent |
gptkb:Genentech
|
| gptkbp:bfsLayer |
4
|